-       Report 
   - January 2025
    -  175 Pages 
    Global
   
   From       €4029EUR$4,490USD£3,536GBP 
                -       Report 
   - November 2025
    -  377 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                -       Report 
   - November 2025
    -  182 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                -       Report 
   - March 2025
    -  185 Pages 
    Global
   
   From       €4038EUR$4,500USD£3,544GBP 
                  -       Drug Pipelines 
   - April 2025
    -  250 Pages 
    Global
   
   From       €2154EUR$2,400USD£1,890GBP 
      €2692EUR$3,000USD£2,363GBP 
                   -       Clinical Trials 
   - April 2025
    -  80 Pages 
    Global
   
   From       €1436EUR$1,600USD£1,260GBP 
      €1795EUR$2,000USD£1,575GBP 
                -       Report 
   - June 2025
    -  110 Pages 
    Global
   
   From       €4397EUR$4,900USD£3,859GBP 
                -       Report 
   - January 2025
    -  175 Pages 
    Global
   
   From       €4029EUR$4,490USD£3,536GBP 
                  -       Report 
   - October 2025
    -  137 Pages 
    Global
   
   From       €2287EUR$2,549USD£2,008GBP 
      €2691EUR$2,999USD£2,362GBP 
                  -       Report 
   - June 2025
    -  146 Pages 
    Global
   
   From       €2287EUR$2,549USD£2,008GBP 
      €2691EUR$2,999USD£2,362GBP 
                -       Report 
   - June 2025
    -  150 Pages 
    Global
   
   From       €2422EUR$2,699USD£2,126GBP 
                -       Report 
   - June 2025
    -  150 Pages 
    Global
   
   From       €2422EUR$2,699USD£2,126GBP 
                -       Report 
   - September 2025
    -  113 Pages 
    Global
   
   From       €3500EUR$4,178USD£3,179GBP 
                -       Report 
   - December 2024
      Japan, United States, ... Japan, United States, Europe, Global 
   
   From       €16601EUR$18,500USD£14,570GBP 
                -       Report 
   - February 2025
      Japan, United States, ... Japan, United States, Europe, Global 
   
   From       €3365EUR$3,750USD£2,953GBP 
                -       Report 
   - December 2024
     United States
   
   From       €2243EUR$2,500USD£1,969GBP 
                -       Report 
   - December 2024
      North America, Mexico, ... North America, Mexico, Canada 
   
   From       €8525EUR$9,500USD£7,482GBP 
                -       Report 
   - February 2025
     Middle East
   
   From       €4038EUR$4,500USD£3,544GBP 
                -       Report 
   - February 2025
      Canada, Mexico, North America Canada, Mexico, North America 
   
   From       €2198EUR$2,450USD£1,930GBP 
                -       Report 
   - February 2025
      Germany, Italy, Spain, ... Germany, Italy, Spain, United Kingdom, Europe, France 
   
   From       €2557EUR$2,850USD£2,245GBP 
             
         Factor IX is a protein used to treat hemophilia B, a rare genetic disorder that impairs the body's ability to form blood clots. It is a recombinant form of the human factor IX protein, which is produced in a laboratory setting. Factor IX is administered intravenously or subcutaneously to replace the missing clotting factor in patients with hemophilia B. It is used to prevent and treat bleeding episodes, as well as to prevent bleeding during surgery.
Factor IX is a part of the larger hematological    drugs market, which includes drugs used to treat blood-related diseases and disorders. These drugs are used to treat a wide range of conditions, including anemia, leukemia, and thrombocytopenia.
Some companies in the Factor IX market include Novo Nordisk, Pfizer, Bayer, and Biogen. Show Less   Read more